<DOC>
	<DOCNO>NCT01787851</DOCNO>
	<brief_summary>Patients dilate cardiomyopathy present indwell right heart catheterization enrol randomize either control triheptanoin oil five day . Hemodynamics assess serially .</brief_summary>
	<brief_title>Study Acute Effects Triheptanoin Heart Failure</brief_title>
	<detailed_description>Consecutive patient DCM present right heart catheterization enrol . All patient present electively hemodynamic assessment PA catheter leave place catheterization part usual care . Post-procedure , patient monitor coronary care unit , routine patient catheter . Patients approach potential enrollment study protocol . The goal enrollment phase protocol 24 patient ( 12 participant receive triheptanoin 10 receive placebo ) . Patients randomly assign receive either triheptanoin oil control treatment ( sugar syrup ) four time day one hour meal night five day . All patient give low fat , low simple sugar diet avoid potential substrate competition high serum level fat glucose duration study procedure . Participants blind treatment assignment . Treatment arm : The standard dose triheptanoin oil adult 1-2gm/kg/24 hour . For purpose study , administer 0.25mg/kg four-times per day . The liquid study drug mixed sugar-free , low fat yogurt , pudding nutritional supplement shake , depend patient preference . Control arm : One tablespoon sugar syrup mixed sugar-free , low fat yogurt , pudding nutritional supplement shake four-times per day meal . Thermodilution cardiac index PCWP measure indwell PA catheter baseline hourly first six hour . During time , initiation upward titration vasodilator inotropic mediation discourage although medication continue patient previously medication . Patients require vasoactive medication urgent basis exclude study participation ( see ) . After first six hour , measurement record day , 90 minute follow ingestion study medication four day treatment , well follow day study medication ( order ass off-treatment hemodynamics ) . Number dose intravenous vasoactive medication record daily . The main outcome interest change cardiac index first 6 hour study period ( initiation vasoactive medication ) . Pre-and post-cardiac index compare pair t-test . With 10 patient per study group , 80 % power detect clinically significant 20 % difference ( 0.4L/min/m2 ) cardiac index treatment assignment . Assuming need non-parametric analysis `` standard '' 20 % increase sample size need seek . Additionally , change cardiac output PCWP five day study period compare group assignment ( control vs. triheptanoin oil ) . Either Friedman 's test ANOVA repeat measure ( depend satisfaction normality assumption ) employ detect serial change treatment . Between-group difference time-point assess two-sample t-test Wilcoxon sign rank test . We also measure off-treatment effect compare day 4 ( final treatment day ) cardiac output PCWP day 6 ( one day treatment ) . Five ( 5 ) cc blood collect EDTA tube PA catheter baseline hourly first six hour study . An additional 5cc blood obtain day 4 day 5 . Serum isolate stored -80C completion study . At time , sample assay metabolic profile , include acylcarnitine fatty acid metabolite . Prior work demonstrate significant increase serum odd-chain fatty acid , acyl-carnitines ketone follow ingestion.These data inform pharmacodynamics triheptanoin metabolism set HF . At baseline day 4 urine sample obtain assayed specie relate proprionate metabolism .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patients eligible inclusion protocol satisfy follow criterion : 1 . DCM leave ventricular ejection fraction ( LVEF ) ≤40 % 2 . New York Heart Association ( NYHA ) class IIIIV symptoms 3. age ≥18 4. indwell PA catheter 5. anticipated clinical requirement PA catheter least five day . Patients ineligible inclusion protocol follow : 1. urgent ( &lt; 6 hr ) need ( increase ) inotropic support ( INTERMACS profile 1 ) 2. diabetes mellitus 3. know disorder respiratory chain mitochondrial cardiomyopathy 4. significant hyperlipidemia triglyceride value &gt; 300mg/dL 5. normal cardiac index ( &gt; 2.5L/min/m2 ) initial right heart catheterization 6. indwell intraaortic balloon pump 7. chronic liver disease 8. severe renal dysfunction ( CKD stage IVV ) creatinine clearance &lt; 30 mL/min/1.73m2 9. moderate valvular stenosis regurgitation 10. pregnancy breastfeed 11. peripartum cardiomyopathy diagnose within past year 12. inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Anaplerosis</keyword>
	<keyword>Medium-chain fatty acid</keyword>
</DOC>